NIH Gifts Brain Drug Patent to Psychedelic Biotech Firm
Published Date: 6/2/2025
Notice
Summary
The National Institutes of Health plan to give Psycala Bio, Inc. an exclusive license to use special new medicines that target the D2 dopamine receptor, which could help treat brain-related conditions. This means Psycala gets the sole right to develop and sell these drugs, potentially speeding up new treatments for patients. Keep an eye out for this exciting change, as it could impact healthcare and business soon!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Exclusive Patent License Granted
The National Institutes of Health is contemplating an Exclusive Patent License to Psycala Bio, Inc. for the inventions listed in the notice. Psycala Bio, Inc., incorporated in Delaware, would receive the exclusive rights to practice the patented inventions described in the Supplementary Information.
D2 Antagonists May Speed Treatments
The license covers exceptionally selective D2 dopamine receptor antagonists, which the notice says could help treat brain-related conditions. The contemplated grant to Psycala could potentially speed development of these therapies for patients.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19718, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding two closed virtual meetings in October 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists and research teams applying for grants should note these dates as they impact funding decisions but don’t involve public attendance.
2026-19804, Submission for OMB Review; 30-Day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)
The NIH is asking for approval to keep collecting info from citizen science and crowdsourcing projects, making it easier to gather public input on health research. This affects anyone involved in these projects and invites comments by October 28, 2026. No new costs or big changes, just a smooth way to keep the data flowing for better science!
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
2026-19706, Draft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participants
The NIH wants to make it easier for people who join clinical studies to get simple summaries of the study results. This new policy aims to boost trust and teamwork between researchers and participants, helping science move faster and better. They’re asking for your thoughts by October 26, 2026, so get ready to share your ideas!
2026-19431, Government-Owned Inventions; Availability for Licensing
The government is offering a new invention for licensing that makes stem cell transplants safer and less harsh, especially for leukemia patients and older folks. This tech uses a special protein to prepare patients for transplants without the tough side effects of chemo and radiation. Companies can start licensing this preclinical innovation now to help bring better treatments to market faster.
Previous / Next Documents
Previous: 2025-09843, Presidential Declaration of a Major Disaster for the State of Missouri
President just declared a major disaster for Missouri after severe storms, tornadoes, and wildfires hit hard. This means extra federal help is on the way to support affected communities and speed up recovery. Residents and local governments can now access emergency funds and resources starting immediately to rebuild and stay safe.
Next: 2025-09845, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in late June and early July 2025 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding to push science forward. If you’re a researcher waiting on grants, these dates are key for your funding chances!